July 16, 2026

How Do Surgical Ovarian Cancer Prevention Strategies Compare for Sexual Function?

A nonrandomized trial found less sexual function impairment with interval salpingectomy with delayed oophorectomy than risk-reducing salpingo-oophorectomy among premenopausal women at high risk for ov...

The ASCO Post

July 16, 2026

Do Sitting Patterns Matter?

Researchers analyzed UK Biobank data to determine whether spending sedentary time in prolonged vs interrupted bouts was associated with subsequent cancer incidence and cancer mortality.

MDSpire News

July 14, 2026

FDA Approves Gedatolisib in Breast Cancer

In VIKTORIA-1, gedatolisib-containing regimens resulted in longer median progression-free survival than fulvestrant alone.

MDSpire News

July 09, 2026

Cancer Screening Gaps Seen in Sexual, Gender Minority Groups

A large BRFSS analysis points to persistent screening disparities among sexual orientation and gender identity minority respondents, with particularly large gaps in some gender identity minority groups.

MDSpire News

July 08, 2026

Self-Sampling Shows Test Agreement

The study authors frame the device as a potential way to simplify screening, while emphasizing that larger validation studies are still needed.

MDSpire News

June 26, 2026

FDA Approves New First-Line TNBC Regimen

Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.

MDSpire News

June 26, 2026

FDA Monthly Preview: Key July Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

MDSpire News

June 26, 2026

Is Accelerated Aging Tied to Early-Onset Carcinogenesis?

Researchers found larger biological age gaps in more recent birth cohorts and observed associations with higher risk of several cancers diagnosed before age 55.

MDSpire News

June 26, 2026

Surveillance May Reduce CIN 2 Overtreatment

Risk-based management may reduce unnecessary excisions in selected patients with CIN 2.

MDSpire News

June 24, 2026

Roswell Park Launches Exclusive Phase 1 Clinical Trial of ‘Armored’ CAR T-Cell Therapy for Ovarian Cancer

Roswell Park Comprehensive Cancer Center is currently recruiting for a phase 1 clinical trial of the new therapy (NCT07489287), called GB-5267, which was co-developed by Roswell Park and the therapeutics company Generate:Biomedicines.

Roswell Park Comprehensive Cancer Center